Proinflammatory effect of TWEAK/Fn14 interaction in human retinal pigment epithelial cells

Current Eye Research

Volumn 34, Issue 10, 2009, Pages 836-844

  Ebihara, Nobuyuki ^a   Nakayama, Masafumi ^a   Tokura, Tomoko ^a   Iwatsu, Minoru ^a   Ushio, Hiroko ^a   Murakami, Akira ^a  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemokine; Fn14; MAP kinase; Retinal pigment epithelial cells; TWEAK

Indexed keywords

ANTIBODY; CHEMOKINE; CYTOKINE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; INTERLEUKIN 8; MITOGEN ACTIVATED PROTEIN KINASE; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS; UNCLASSIFIED DRUG; VASCULOTROPIN;

ARTICLE; CELL CULTURE; CELL MIGRATION; CELL STIMULATION; CELL VIABILITY; CLINICAL ASSESSMENT; CONTROLLED STUDY; CYTOKINE PRODUCTION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; PIGMENT CELL; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; SUPERNATANT;

CELL LINE; CELL MOVEMENT; CHEMOKINE CCL2; FIBROBLAST GROWTH FACTORS; FLOW CYTOMETRY; HUMANS; INFLAMMATION; INTERLEUKIN-8; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; RECEPTORS, TUMOR NECROSIS FACTOR; RETINAL PIGMENT EPITHELIUM; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 70449481109     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.3109/02713680903122037     Document Type: Article

References (61)

1. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997;272:32401-32410.
2. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-8459.
3. Ho DH, Vu H, Brown SA, Donohue PJ, Hanscom HN, Winkles JA. Soluble tumor necrosis factor-like weak inducer of apoptosis overexpression in HEK293 cells promotes tumor growth and angiogenesis in athymic nude mice. Cancer Res 2004;64:8968-8972
4. Kawakita T, Shiraki K, Yamanaka Y, Yamaguchi Y, Saitou Y, Enokimura N, Yamamoto N, Okano H, Sugimoto K, Murata K, Nakano T. Functional expression of TWEAK in human hepatocellular carcinoma: Possible implication in cell proliferation and tumor angiogenesis. Biochem Biophys Res Commun 2004;318:726-733.
5. Harada N, Nakayama M, Nakano H, Fukuchi Y, Yagita H, Okumura K. Proinflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells. Biochem Biophys Res Commun 2002;299:488-493.
6. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003;14:241-249.
7. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H. TWEAK is a novel arthritogenic mediator. J Immunol 2006;177: 2610-2620.
8. Wiley SR, Cassiano L, Lofton T, Davis-Smith T, Winkles JA, Lindner V, Liu H, Daniel TO, Smith CA, Fanslow WC. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 2001;15:837-846.
9. Jakubowski A, Browning B, Lukashev M, Sizing I, Thompson JS, Benjamin CD, Hsu YM, Ambrose C, Zheng TS, Burkly LC. Dual role for TWEAK in angiogenic regulation. J Cell Sci 2002;115:267-274.
10. Lynch CN, Wang YC, Lund JK, Chen YW, Leal JA, Wiley SR. TWEAK induces angiogenesis and proliferation of endothelial cells. J Biol Chem 1999;274:8455-8459.
11. Potrovita I, Zhang W, Burkly L, Hahm K, Lincecum J, Wang MZ, Maurer MH, Rossner M, Schneider A, Schwaninger M. Tumor necrosis factor-like weak inducer of apoptosis-induced neurodegeneration. J Neurosci 2004;24:8237-8244.
12. Xu H, Okamoto A, Ichikawa J, Ando T, Tasaka K, Masuyama K, Ogawa H, Yagita H, Okumura K, Nakao A. TWEAK/Fn14 interaction stimulates human bronchial epithelial cells to produce IL-8 and GM-CSF. Biochem Biophys Res Commun 2004;318:422-427.
13. Jin L, Nakao A, Nakayama M, Yamaguchi N, Kojima Y, Nakano N, Tsuboi R, Okumura K, Yagita H, Ogawa H. Induction of RANTES by TWEAK/Fn14 interaction in human keratinocytes. J Invest Dermatol 2004;122:1175-1179.
14. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003;23:594-600.
15. Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S. TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem 2003;278:36005-36012.
16. Meighan-Mantha RL, Hsu DK, Guo Y, Guo Y, Brown SA, Feng SL, Peifley KA, Alberts GF, Copeland NG, Gilbert DJ, Jenkins NA, Richards CM, Winkles JA. Themitogen-inducible Fn14 gene encodes a type I transmembrane protein that modulates fibroblast adhesion and migration. J Biol Chem 1999;274:33166-33176.
17. Perper SJ, Browning B, Burkly LC, Weng S, Gao C, Giza K, Su L, Tarilonte L, Crowell T, Rajman L, Runkel L, Scott M, Atkins GJ, Findlay DM, Zheng TS, Hess H. TWEAK is a novel arthritogenic mediator. J Immunol 2006;177: 2610-2620.
18. Kamata K, Kamijo S, Nakajima A, Koyanagi A, Kurosawa H, Yagita H, Okumura K. Involvement of TNF-like weak inducer of apoptosis in the pathogenesis of collageninduced arthritis. J Immunol 2006;177:6433-6439.
19. Zhao Z, Burkly LC, Campbell S, Schwartz N, Molano A, Choudhury A, Eisenberg RA, Michaelson JS, Putterman C. TWEAK/Fn14 interactions are instrumental in the pathogenesis of nephritis in the chronic graft-versushost model of systemic lupus erythematosus. J Immunol 2007;179:7949-7958.
20. Campbell S, Michaelson J, Burkly L, Putterman C. The role of TWEAK/Fn14 in the pathogenesis of inflammation and systemic autoimmunity. Front Biosci 2004;9:2273-2284.
21. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242-250.
22. Desplat-Jego S, Varriale S, Creidy R, Terra R, Bernard D, Khrestchatisky M, Izui S, Chicheportiche Y, Boucraut J. TWEAK is expressed by glial cells, induces astrocyte proliferation, and increases EAE severity. J Neuroimmunol 2002;133:116-123.
23. Mueller AM, Pedré X, Kleiter I, Hornberg M, Steinbrecher A, Giegerich G. Targeting fibroblast growth factor-inducible- 14 signaling protects from chronic relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2005;159:55-65.
24. Desplat-Jego S, Creidy R, Varriale S, Allaire N, Luo Y, Bernard D, Hahm K, Burkly L, Boucraut J. Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. Clin Immunol 2005; 117:15-23.
25. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M, Stumvoll M, Fasshauer M. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008;199:440-444.
26. Nagasawa M, Yi Z, Imashuku S, Nonoyama S, Ogawa K, Okumura K, Mizutani S. Soluble TWEAK is markedly elevated in hemophagocytic lymphohistiocytosis. Am J Hematol 2007;83:222-225.
27. Schwartz N, Su L, Burkly LC, Mackay M, Aranow C, Kollaros M, Michaelson JS, Rovin B, Putterman C. Urinary TWEAK and the activity of lupus nephritis. J Autoimmun 2006;27:242-250.
28. Holtkamp GM, Van Rossem M, de Vos AF, Willekens B, Peek R, Kijlstra A. Polarized secretion of IL-6 and IL-8 by human retinal pigment epithelial cells. Clin Exp Immunol 1998;112:34-43.
29. 2) by human retinal pigment epithelial cells. Clin Exp Immunol 1999;118:35-40.
30. Erger RA, Casale TB. Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium. Am J Physiol 1995;268:L117-L122.
31. Yoshimura T, Robinson EA, Tanaka S, Appella E, Leonard EJ. Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes. J Immunol 1989;142:1956-1962.
32. Taub DD, Proost P, Murphy WJ, Anver M, Longo DL, van Damme J, Oppenheim JJ. Monocyte chemotactic protein-1 (MCP-1), -2, and -3 are chemotactic for human T lymphocytes. J Clin Invest 1995;95:1370-1376.
33. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045-1053.
34. Yoshida A, Yoshida S, Khalil AK, Ishibashi T, Inomata H. Role of NF-kappaB-mediated interleukin-8 expression in intraocular neovascularization. Invest Ophthalmol Vis Sci 1998;39:1097-1106.
35. Cassidy L, Barry P, Shaw C, Duffy J, Kennedy S. Platelet derived growth factor and fibroblast growth factor basic levels in the vitreous of patients with vitreoretinal disorders. Br J Ophthalmol 1998;82:181-185.
36. Kon CH, Occleston NL, Aylward GW, Khaw PT. Expression of vitreous cytokines in proliferative vitreoretinopathy: A prospective study. Invest Ophthalmol Vis Sci 1999; 40:705-712.
37. Limb GA, Little BC, Meager A, Ogilvie JA, Wolstencroft RA, Franks WA, Chignell AH, Dumonde DC. Cytokines in proliferative vitreoretinopathy. Eye 1991;5:686-693.
38. Wiedemann P. Growth factors in retinal disease: Proliferative vitreoretinopathy, proliferative diabetic retinopathy, and retinal degeneration. Surv Ophthalmol 1992;36:373-384.
39. Briggs MC, Grierson I, Hiscott P, Hunt JA. Active scatter factor (HGF/SF) in proliferative vitreoretinal disease. Invest Ophthalmol Vis Sci 2000;41:3085-3094.
40. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Hepatocyte growth factor levels in the vitreous of patients with proliferative vitreoretinopathy. Am J Ophthalmol 2000;129:678-680. (Pubitemid 30323744)
41. Elner SG, Elner VM, Jaffe GJ, Stuart A, Kunkel SL, Strieter RM. Cytokines in proliferative diabetic retinopathy and proliferative vitreoretinopathy. Curr Eye Res 1995;14:1045-1053.
42. Aksunger A, Or M, Okur H, Hasanreisoglu B, Akbatur H. Role of interleukin-8 in the pathogenesis of proliferative vitreoretinopathy. Ophthalmologica 1997;211:223-225.
43. Abu El-Asrar AM, Van Damme JO, Put W, Veckeneer M, Dralands L, Billiau A, Missotten L. Monocyte chemotactic protein-1 in proliferative vitreoretinal disorders. Am J Ophthalmol 1997;123:599-606.
44. Capeans C, De Rojas MV, Lojo S, Salorio MS. C-C chemokines in the vitreous of patients with proliferative vitreoretinopathy and proliferative diabetic retinopathy. Retina 1998;18:546-550.
45. Elner SG, Strieter R, Bian ZM, Kunkel S, Mokhtarzaden L, Johnson M, Lukacs N, Elner VM. Interferon-induced protein-10 and interleukin-8. C-X-C chemokines present in proliferative diabetic retinopathy. Arch Ophthalmol 1998;116:1597-1601.
46. Yuuki T, Kanda T, Kimura Y, Kotajima N, Tamura J, Kobayashi I, Kishi S. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complic 2001;15:257-259. (Pubitemid 32750613)
47. Mitamura Y, Takeuchi S, Matsuda A, Tagawa Y, Mizue Y, Nishihira J. Monocyte chemotactic protein-1 in patients with proliferative diabetic retinopathy. Ophthalmologica 2001;215:415-418
48. Cicik E, Tekin H, Akar S, Ekmekci OB, Donma O, Koldas L, Ozkan S. Interleukin-8, nitric oxide, and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy. Ophthalmic Res 2003;35:251-255.
49. Lutty G, Merges C, Threlkeld A, Crone S, McLeod S. Heterogeneity in localization of TGF-b in human retina, vitreous, and choroid. Invest Ophthalmol Vis Sci 1993;34:477-487.
50. Tanihara H, Yoshida M, Matsumoto M, Yoshimura N. Identification of transforming growth factor-b expressed in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1993;34:413-419.
51. Pfeffer BA, Flanders KC, Guérin CJ, Danielpour D, Anderson DH. Transforming growth factor-b2 is the predominant isoform in the neural retina, retinal pigment epithelium-choroid, and vitreous of the monkey eye. Exp Eye Res 1994;59:323-333.
52. Conner TB, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG, de Bustros S, Enger C, Kato H, Lansing M, Hayashi H, Glaser BM. Correlation of fibrosis and transforming growth factor-b type 2 levels in the eye. J Clin Invest 1989;83:1661-1666.
53. Bochaton-Piallat ML, Kapetanios AD, Donati G, Redard M, Gabbiani G, Pournaras CJ. TGF-β 1, TGF-β receptor II, and ED-A fibronectin expression in myofibroblast of vitreoretinopathy. Invest Ophthalmol Vis Sci 2000;41: 2336-2342.
54. Seger R, Krebs EG. The MAPK signaling cascade. FASEB J 1995;9:726-735.
55. Donohue PJ, Richards CM, Brown SA, Hanscom HN, Buschman J, Thangada S, Hla T, Williams MS, Winkles JA. TWEAK is an endothelial cell growth and chemotactic factor that also potentiates FGF-2 and VEGF-A mitogenic activity. Arterioscler Thromb Vasc Biol 2003;23:594-600.
56. Hinton DR, He S, Graf K, Yang D, Hsueh WA, Ryan SJ, Law RE. Mitogen-activated protein kinase activation mediates PDGF-directed migration of RPE cells. Exp Cell Res 1998;239:11-15.
57. Jin M, He S, Wörpel V, Ryan SJ, Hinton DR. Promotion of adhesion and migration of RPE cells to provisional extracellular matrices by TNF-α. Invest Ophthalmol Vis Sci 2000;41:4324-4332.
58. Hecquet C, Lefevre G, Valtink M, Engelmann K, Mascarelli F. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation. Invest Ophthalmol Vis Sci 2002;43:3091-3098.
59. Liou GI, Matragoon S, Samuel S, Behzadian MA, Tsai NT, Gu X, Roon P, Hunt DM, Hunt RC, Caldwell RB, Marcus DM. MAP kinase and beta-catenin signaling in HGF-induced RPE migration. Mol Vis 2002;8:483-493.
60. Geller SF, Lewis GP, Fisher SK. FGFR1, signaling, and AP-1 expression after retinal detachment: Reactive Müller and RPE cells. Invest Ophthalmol Vis Sci 2001;42:1363-1369.
61. Liou GI, Pakalnis VA, Matragoon S, Samuel S, Behzadian MA, Baker J, Khalil IE, Roon P, Caldwell RB, Hunt RC, Marcus DM. HGF regulation of RPE proliferation in an IL-1beta/retinal hole-induced rabbit model of PVR. Mol Vis 2002;8:494-501.